

Contact:

Douglas Doerfler
President & CEO
MaxCyte, Inc.
(301) 944-1700

For Immediate Release

MaxCyte to Present at the BIO CEO & Investor Conference

Gaithersburg, MD, February 7, 2007 – MaxCyte, Inc., a clinical stage therapeutic company and pioneer in clinical scale, non-viral cell loading systems, announces Douglas Doerfler, President & CEO, will be presenting at the BIO CEO & Investor Conference in New York, Waldorf=Astoria, on Monday, February 12, 2007 at 11:00 am.

Mr. Doerfler will provide a brief corporate overview and discuss the company's preclinical and clinical product portfolio, partnering candidates, and enabling technology for therapeutic development and biotherapeutic manufacturing.

About MaxCyte

MaxCyte is a clinical-stage cell therapeutics company with a rapidly growing pipeline of product development partnerships in cell-based therapies. The Company's proprietary *ex vivo* cell loading technology overcomes critical obstacles such as safety, scalability and reproducibility which are fundamental to successful cell-based therapies. MaxCyte has demonstrated the value of its versatile technology in partnered therapeutic programs in oncology, pulmonary, metabolic and infectious diseases as well as in development collaborations with leading researchers. Current clinical programs with MaxCyte-engineered cells include a Phase I/II clinical study for treatment of chronic lymphocytic leukemia (CLL) and a Phase IIa study for the treatment of primary Pulmonary Arterial Hypertension (PAH). In addition, there are advanced preclinical programs in oncology and regenerative medicine. More than 16 commercial and academic partners are currently using the MaxCyte technology. The MaxCyte system has an FDA Master File in place at CBER.

For more information, visit <http://www.maxcyte.com>.

This press release may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties.

###